Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie-Eve Beaulieu

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Journal of Molecular Recognition : JMR|June 27, 2012
New structural determinants for c-Myc specific heterodimerization with Max and development of a novel homodimeric c-Myc b-HLH-LZMarie-Eve Beaulieu, François-Olivier McDuff, Vincent Frappier, et al.
The Journal of Biological Chemistry|July 5, 2003
Constitutive activation of the angiotensin II type 1 receptor alters the spatial proximity of transmembrane 7 to the ligand-binding pocketAntony A Boucard, Marise Roy, Marie-Eve Beaulieu, et al.
The Journal of Biological Chemistry|December 23, 2003
Structural determinants regulating expression of the high affinity leukotriene B4 receptor: involvement of dileucine motifs and alpha-helix VIIIRémi Gaudreau, Marie-Eve Beaulieu, Zhangguo Chen, et al.
The Journal of Biological Chemistry|May 14, 2005
Determining the environment of the ligand binding pocket of the human angiotensin II type I (hAT1) receptor using the methionine proximity assayMartin Clément, Stéphane S Martin, Marie-Eve Beaulieu, et al.
Biochemical Pharmacology|May 12, 2009
Identification of transmembrane domain 6 & 7 residues that contribute to the binding pocket of the urotensin II receptorBrian J Holleran, Ivana Domazet, Marie-Eve Beaulieu, et al.
Biochemistry|November 27, 2002
Residues 293 and 294 are ligand contact points of the human angiotensin type 1 receptorJacqueline Pérodin, Maud Deraët, Mannix Auger-Messier, et al.
Oncotarget|May 4, 2018
BET inhibition is an effective approach against KRAS-driven PDAC and NSCLCToni Jauset, Daniel Massó-Vallés, Sandra Martínez-Martín, et al.
Cancers|February 11, 2023
Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor TissueMarie-Eve Beaulieu, Sandra Martínez-Martín, Jastrinjan Kaur, et al.
Cancer Research|April 17, 2015
Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinomaDaniel Massó-Vallés, Toni Jauset, Erika Serrano, et al.
The EMBO Journal|April 1, 2021
Integrated requirement of non-specific and sequence-specific DNA binding in Myc-driven transcriptionPaola Pellanda, Mattia Dalsass, Marco Filipuzzi, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Journal of Molecular Recognition : JMR|June 27, 2012
New structural determinants for c-Myc specific heterodimerization with Max and development of a novel homodimeric c-Myc b-HLH-LZMarie-Eve Beaulieu, François-Olivier McDuff, Vincent Frappier, et al.
The Journal of Biological Chemistry|July 5, 2003
Constitutive activation of the angiotensin II type 1 receptor alters the spatial proximity of transmembrane 7 to the ligand-binding pocketAntony A Boucard, Marise Roy, Marie-Eve Beaulieu, et al.
The Journal of Biological Chemistry|December 23, 2003
Structural determinants regulating expression of the high affinity leukotriene B4 receptor: involvement of dileucine motifs and alpha-helix VIIIRémi Gaudreau, Marie-Eve Beaulieu, Zhangguo Chen, et al.
The Journal of Biological Chemistry|May 14, 2005
Determining the environment of the ligand binding pocket of the human angiotensin II type I (hAT1) receptor using the methionine proximity assayMartin Clément, Stéphane S Martin, Marie-Eve Beaulieu, et al.
Biochemical Pharmacology|May 12, 2009
Identification of transmembrane domain 6 & 7 residues that contribute to the binding pocket of the urotensin II receptorBrian J Holleran, Ivana Domazet, Marie-Eve Beaulieu, et al.
Biochemistry|November 27, 2002
Residues 293 and 294 are ligand contact points of the human angiotensin type 1 receptorJacqueline Pérodin, Maud Deraët, Mannix Auger-Messier, et al.
Oncotarget|May 4, 2018
BET inhibition is an effective approach against KRAS-driven PDAC and NSCLCToni Jauset, Daniel Massó-Vallés, Sandra Martínez-Martín, et al.
Cancers|February 11, 2023
Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor TissueMarie-Eve Beaulieu, Sandra Martínez-Martín, Jastrinjan Kaur, et al.
Cancer Research|April 17, 2015
Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinomaDaniel Massó-Vallés, Toni Jauset, Erika Serrano, et al.
The EMBO Journal|April 1, 2021
Integrated requirement of non-specific and sequence-specific DNA binding in Myc-driven transcriptionPaola Pellanda, Mattia Dalsass, Marco Filipuzzi, et al.
Pageof 3